Table 4.
Multivariate association of 24-week OS with serum miR-122 concentration according to HBV-DNA or HBeAg status.
| 24-week OSa (n) | Total (n) | Univariate HR (95%CI)a | Multivariate HR (95%CI)a,b | |
|---|---|---|---|---|
| Positive HBV-DNAc | ||||
| miR122_L group | 54 | 77 | Reference | Reference |
| miR122_H group | 57 | 73 | 1.11 (0.92∼1.35) | 1.12 (0.93∼1.35) |
|
| ||||
| Negative HBV-DNA | ||||
| miR122_L group | 149 | 217 | Reference | Reference |
| miR122_H group | 184 | 221 | 1.21 (1.09∼1.35) | 1.22 (1.09∼1.36) |
|
| ||||
| Positive HBeAg | ||||
| miR122_L group | 48 | 68 | Reference | Reference |
| miR122_H group | 41 | 59 | 0.98 (0.78∼1.24) | 0.99 (0.78∼1.25) |
|
| ||||
| Negative HBeAg | ||||
| miR122_L group | 155 | 226 | Reference | Reference |
| miR122_H group | 200 | 235 | 1.24 (1.12∼1.38) | 1.25 (1.13∼1.39) |
aOS: overall survival; HR: hazard ratio; CI: confidence interval. bThe multivariate COX model was adjusted by gender, age, annual income, HBeAg, HBV-DNA, serum albumin, serum total bilirubin, serum fetoprotein, ECOG score, maximum diameter of tumor, number of tumors, extent of tumor, portal vein invasion, and hepatic vein invasion. cPositive HBV-DNA was defined as HBV-DNA ≥ 103 copies/ml.